Didanosine and foscarnet marketed for use by patients with AIDS.
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000188:drug therapy*; D000998:Antiviral Agents / Q000627:therapeutic use*; D003586:Cytomegalovirus Infections / Q000150:complications / Q000188:drug therapy*; D016049:Didanosine / Q000627:therapeutic use*; D017245:Foscarnet; D006801:Humans; D010746:Phosphonoacetic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012173:Retinitis / Q000150:complications / Q000188:drug therapy*; D014481:United States; D014486:United States Food and Drug Administration
D000998:Antiviral Agents; D017245:Foscarnet; D016049:Didanosine; D010746:Phosphonoacetic Acid